Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

DDR

This page shows the latest DDR news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca to present new oncology data at AACR

AstraZeneca to present new oncology data at AACR

DNA Damage Response (DDR) and Antibody Drug Conjugate (ADC) scientific platforms.

Latest news

  • AZ showcases data for next-generation PARP inhibitor AZD5305 AZ showcases data for next-generation PARP inhibitor AZD5305

    PARP inhibitors work to prevent cancer cells from repairing, by blocking PARP enzymes which help to repair DNA damage in cells – also known as the DNA damage response (DDR) pathway. ... Like PARP inhibitors, the inhibition of WEE1 is focused on the DDR

  • Merck KGaA signs deal with Artios Pharma potentially worth up to $860m Merck KGaA signs deal with Artios Pharma potentially worth up to $860m

    Artios’ management team are experts in the DNA damage response (DDR) field and were involved in developing olaparib, the first DDR inhibitor, now on its way to becoming a blockbuster for ... This collaboration further strengthens our leadership and

  • Evotec spins off cancer tech into new Breakpoint company Evotec spins off cancer tech into new Breakpoint company

    Will challenge AstraZeneca and others in DNA damage response. German biotech Evotec has decided to bundle its cancer therapeutic programmes focused on DNA damage response (DDR) into a new spin-off ... Spinning the programmes into a stand-alone company

  • UK biotech Artios Pharma appoints new medical director UK biotech Artios Pharma appoints new medical director

    He will focus on helping Artios progress its pipeline of first-in-class DNA damage response (DDR) therapies. ... The company is developing a next generation of DDR therapies, targeting mechanisms such as the down-regulation or loss of certain DNA repair

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    Baselga also confirmed that it will "highlight an exciting new phase of scientific discovery", in the form of a new wave of DNA Damage Response (DDR) targets. ... Moving its DDR pipeline beyond PARP inhibition, AZ will share data on a potent and

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    is furthering work in DNA damage response (DDR), a key platform in oncology.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    She says understanding about the role of a host of other DDR pathways and mechanisms is deepening – and AstraZeneca is leading the industry. ... So that’s the rationale behind combinations of DDR agents with immuno-oncology.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Artios Pharma appoints science strategy VP Artios Pharma appoints science strategy VP

    Dr Boulton joins the newly-launched oncology specialist to lead the development of the company's two lead DNA Damage Response (DDR) programmes as well as assisting the business development team ... first-in-class DDR programmes and establish Artios as a

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Time to talk about health inequalities
Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...

Quick links